Donovan Quill, President and CEO, Optime Care, interview featured on November 16, 2021.
A new study shows that the estimated economic cost of 379 rare diseases reached nearly $1 trillion in the U.S. in 2019, driven by indirect costs, including productivity loss of $437 billion. This reveals a massive economic toll on patients, caregivers and employers.
To help optimize care – and mitigate the economic burden of specialty drugs — a patient-first approach can enable pharmaceutical companies, pharmacists, physicians and other members of the care team to better address compliance and adherence to treatment, improve outcomes and enhance quality of life for patients.
This article focuses on how a patient-first strategy not only connects physicians, specialty pharmacy, patients and care coordinators, but also strengthens communication, offers a higher level of care continuity and yields rich data for more informed decision making.